HomeAI · summaries
Storia in 4 fonti
Eli Lilly Eyes Label Expansion For Leukemia Drug - Eli Lilly (NYSE:LLY)
Eli Lilly's Phase 3 BRUIN CLL-322 study showed Jaypirca combination therapy cut progression or death risk by 45% in CLL/SLL.
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
endpoints.news
Lilly puts its stamp at EHA with Jaypirca combo data in CLL, first clinical data from Ajax buyout
Eli Lilly made a push in blood cancer at this year’s European Hematology Association presenting data for Jaypirca as well as its first-ever clinical trial results in myelofibrosis.
- ·
fiercepharma.com
Lilly oncology chief went from ‘extremely nervous’ to ‘blown away’ by new Jaypirca CLL data
In patients with BTK-pretreated chronic lymphocytic leukemia (CLL), AbbVie and Roche’s Venclexta (venetoclax) is the drug to beat. | In patients with BTK-pretreated chronic…
